News
ILMN
123.13
+1.72%
2.08
Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)
Illumina, Inc. (NASDAQ:ILMN) has a fair value estimate of US$144 per share. We use a discounted cash flow model to estimate the value of Illumina. The company is valued at a 16% discount to its current share price. The model is based on a 2-stage growth rate for the company's future cash flows. Illumina appears to be trading close to its estimated fair value, at US$121.
Simply Wall St · 12h ago
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
NASDAQ · 1d ago
Baron Focused Growth Fund Q1 2024 Shareholder Letter
Baron Focused Growth Fund increased 1.68% in the first quarter. The Fund underperformed the Russell 2500 Growth Index, which increased 8.51%. The Fund has continued to generate strong returns with less than market risk. Baron is an asset management firm focused on delivering growth equity investment solutions.
Seeking Alpha · 2d ago
Top high growth investment ratio stocks from each sector - GS
Goldman Sachs analysts listed the top stocks in each sector with the highest growth investment ratio. Analysts said they forecast capex and R&D growth to slow from about 10% in 2023 to about 7% in 2024. Growth investment ratio is defined as a company's capex less depreciation plus R&d as a share of its cash flow.
Seeking Alpha · 4d ago
Weekly Report: what happened at ILMN last week (0415-0419)?
Weekly Report · 4d ago
ILLUMINA INC <ILMN.O>: HSBC CUTS TARGET PRICE TO $130 FROM $140
Reuters · 4d ago
Analysts Anticipate 12% Upside For The Holdings of IVE
NASDAQ · 04/17 14:04
The Cathie Wood Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving
Investorplace · 04/16 18:47
Notable Tuesday Option Activity: META, ILMN, COST
NASDAQ · 04/16 17:19
Nasdaq 100 Movers: TSLA, AMD
NASDAQ · 04/16 14:22
Weekly Report: what happened at ILMN last week (0408-0412)?
Weekly Report · 04/15 09:09
ROBO ETF: A Diversified Investment Into The Future
ROBO Global Robotics and Automation Index ETF invests in global companies involved in automation, AI, and robotics. The ETF is mostly focused on industry leaders from the U.S., but also includes companies from other countries. ROBO has underperformed other robotic funds but offers a diversified approach with a focus on small-cap stocks.
Seeking Alpha · 04/15 02:00
Looking Into Illumina's Recent Short Interest
Illumina's short percent of float has risen 5.16% since its last report. The company has 5.21 million shares sold short, which is 3.67% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 04/12 15:45
Stocks with the least price swings, most attractive option-sale candidates - JPM
Stocks with the least price swings, most attractive option-sale candidates. J.P. Morgan analysts listed stocks with the lowest range bound score to identify the least swings in price over the past three months. The Coca-Cola Co. Is one of the most attractive stocks to buy.
Seeking Alpha · 04/12 14:44
Illumina Gains Approval for GRAIL Divestiture Plans
TipRanks · 04/12 13:12
ILLUMINA'S PLANNED DIVESTMENT OF GRAIL APPROVED BY THE EUROPEAN COMMISSION
Reuters · 04/12 13:00
ILLUMINA INC: CONTINUES TO EXPLORE DIVESTING GRAIL THROUGH EITHER TRADE SALE OR CAPITAL MARKETS TRANSACTION
Reuters · 04/12 13:00
ILLUMINA: IN EVENT OF CAPITAL MARKETS TRANSACTION, CO MUST CAPITALIZE GRAIL WITH 2-1/2 YEARS OF FUNDING, WHICH IS ESTIMATED AT ABOUT $1 BLN
Reuters · 04/12 13:00
ILLUMINA INC <ILMN.O>: LEERINK PARTNERS CUTS TARGET PRICE TO $155 FROM $170
Reuters · 04/12 12:02
More
Webull provides a variety of real-time ILMN stock news. You can receive the latest news about Illumina Inc through multiple platforms. This information may help you make smarter investment decisions.
About ILMN
Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.